Capricor Therapeutics Q2 EPS $(0.29) Beats $(0.35) Estimate, Sales $3.92M Beat $1.50M Estimate
Portfolio Pulse from sunil@benzinga.com
Capricor Therapeutics reported Q2 earnings per share of $(0.29), beating the analyst consensus estimate of $(0.35) by 17.14%. The company also reported quarterly sales of $3.92 million, surpassing the analyst consensus estimate of $1.50 million by 161.13%.
August 07, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics reported better than expected Q2 earnings and sales, which could positively impact the stock in the short term.
Capricor Therapeutics reported Q2 earnings and sales that beat analyst estimates. This is generally seen as positive news and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100